Podcasts & RSS Feeds
Most Active Stories
- Hartford Student, Born in a Nepali Refugee Camp, Prepares for College
- "Peter Pan": a Critique of Pure Snark
- Waterbury Hospital CEO Calls on Gov. Malloy to Help Salvage Tenet Deal
- Hartford Mayoral Possibilities Start to Emerge
- Biological Explanations for Mental Health Symptoms Make Clinicians Less Empathetic
Thu May 15, 2014
A History of Drugs, Compiled
A Yale scientist is in the midst of a 20-paper series studying the history of drug development in the United States. Michael Kinch, the managing director of Yale's Center for Molecular Discovery, has spent the last year creating a massive database of compounds approved by the FDA.
In case you're curious, that's 1,453 drugs. The earliest one Kinch identified was morphine, which came to the U.S. after Merck started selling it in Germany in 1827. "We first made the list," Kinch said. "Then the question became, what all has happened to these drugs? Who wrote the first publication? Who did the clinical trials on it? Then: what was the fate of these companies?"
Kinch said that today, ten drug companies control two-thirds of all drugs. Smaller groups are often acquired by bigger ones, which are scaling back internal research and development. That means the infrastructure to create new drugs, or modify existing ones, could be shrinking.
"The fundamentals," Kinch said, "are that we need to come up with new ways to be faster, more efficient, and more accurate -- more right in screening new drugs, so we can turn around a new idea that comes out of the laboratories at universities like Yale, and turn them into something that could be a medicine."
Here's another issue: Kinch said that historically, drug development has been market-driven. Oncology, for example, during the 1990s, was seen as non-lucrative. "Nowadays," Kinch said, "the exact opposite is happening. Everybody is flocking into oncology. There are certain interesting questions. Cardiovascular diseases, which remain the number one cause of morbidity and mortality, are really not proportionally being represented by pharmaceutical companies."
The articles are scheduled to be published over the next year in the journal Drug Discovery Today.